Wang Xing, Yang Jinshou, Ren Bo, Yang Gang, Liu Xiaohong, Xiao Ruiling, Ren Jie, Zhou Feihan, You Lei, Zhao Yupei
Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100023, China.
Key Laboratory of Research in Pancreatic Tumor, Chinese Academy of Medical Sciences, Beijing 100023, China.
Genes Dis. 2023 Oct 14;11(6):101143. doi: 10.1016/j.gendis.2023.101143. eCollection 2024 Nov.
Pancreatic cancer, a highly fatal malignancy, is predicted to rank as the second leading cause of cancer-related death in the next decade. This highlights the urgent need for new insights into personalized diagnosis and treatment. Although molecular subtypes of pancreatic cancer were well established in genomics and transcriptomics, few known molecular classifications are translated to guide clinical strategies and require a paradigm shift. Notably, chronically developing and continuously improving high-throughput technologies and systems serve as an important driving force to further portray the molecular landscape of pancreatic cancer in terms of epigenomics, proteomics, metabonomics, and metagenomics. Therefore, a more comprehensive understanding of molecular classifications at multiple levels using an integrated multi-omics approach holds great promise to exploit more potential therapeutic options. In this review, we recapitulated the molecular spectrum from different omics levels, discussed various subtypes on multi-omics means to move one step forward towards bench-to-beside translation of pancreatic cancer with clinical impact, and proposed some methodological and scientific challenges in store.
胰腺癌是一种高度致命的恶性肿瘤，预计在未来十年将成为癌症相关死亡的第二大主要原因。这凸显了对个性化诊断和治疗获得新见解的迫切需求。尽管胰腺癌的分子亚型在基因组学和转录组学中已得到充分确立，但很少有已知的分子分类被转化为指导临床策略，并且需要范式转变。值得注意的是，长期发展且不断改进的高通量技术和系统是进一步从表观基因组学、蛋白质组学、代谢组学和宏基因组学方面描绘胰腺癌分子图景的重要驱动力。因此，使用综合多组学方法在多个层面更全面地理解分子分类，有望挖掘更多潜在的治疗选择。在这篇综述中，我们概述了来自不同组学层面的分子谱，讨论了基于多组学方法的各种亚型，以朝着具有临床影响的胰腺癌从实验台到床边的转化再迈进一步，并提出了一些即将面临的方法学和科学挑战。
